Piśmiennictwo

1. Bouvier-Colle MH, Mohangoo AD, Gissler M, et al. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. BJOG. 2012; 119(7): 880–889; discussion 890, doi: 10.1111/j.1471-0528.2012.03330.x, indexed in Pubmed: 22571748.
2. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011; 118 Suppl 1: 1–203, doi: 10.1111/j.1471-0528.2010.02847.x, indexed in Pubmed: 21356004.
3. Knight M, Nair M, Tuffnell D, et al. (Eds.) on behalf of MBRRACE-UK. Saving lives, improving mothers' care - surveillance of maternal deaths in the UK 2012–14 and lessons learned to inform maternity care from the uk and ireland confidential enquiries into maternal deaths and morbidity 2009–14. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2016.
4. van Hagen IM, Boersma E, Johnson MR, et al. ROPAC investigators and EORP team. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. Eur J Heart Fail. 2016; 18(5): 523–533, doi: 10.1002/ejhf.501, indexed in Pubmed: 27006109.
5. Elkayam U, Goland S, Pieper PG, et al. High-Risk Cardiac Disease in Pregnancy: Part I. J Am Coll Cardiol. 2016; 68(4): 396–410, doi: 10.1016/j.jacc.2016.05.048, indexed in Pubmed: 27443437.
6. Farr A, Lenz-Gebhart A, Einig S, et al. Outcomes and trends of peripartum maternal admission to the intensive care unit. Wien Klin Wochenschr. 2017; 129(17-18): 605–611, doi: 10.1007/s00508-016-1161-z, indexed in Pubmed: 28101669.
7. Hermus MAA, Wiegers TA, Hitzert MF, et al. The Dutch Birth Centre Study: study design of a programmatic evaluation of the effect of birth centre care in the Netherlands. BMC Pregnancy Childbirth. 2015; 15: 148, doi: 10.1186/s12884-015-0585-1, indexed in Pubmed: 26174336.
8. de Jonge L, Garne E, Gini R, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study. Drug Saf. 2015; 38(11): 1083–1093, doi: 10.1007/s40264-015-0321-9, indexed in Pubmed: 26153398.
9. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Scientific Document Group, European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32(24): 3147–3197, doi: 10.1093/eurheartj/ehr218, indexed in Pubmed: 21873418.
10. Nishimura R, Otto C, Bonow R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2014; 63(22): e57–e185, doi: 10.1016/j.jacc.2014.02.536, indexed in Pubmed: 24603191.
11. Pijuan-Domènech A, Galian L, Goya M, et al. Cardiac complications during pregnancy are better predicted with the modified WHO risk score. Int J Cardiol. 2015; 195: 149–154, doi: 10.1016/j.ijcard.2015.05.076, indexed in Pubmed: 26043149.
12. Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci_on Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017; 19: 465–511, doi: doi: 10.1093/europace/euw301, indexed in Pubmed: 27856540.
13. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106(2): 401–407, doi: 10.1182/blood-2005-02-0626, indexed in Pubmed: 15811953.
14. McDonnell BP, Glennon K, McTiernan A, et al. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism. J Thromb Thrombolysis. 2017; 43(1): 105–111, doi: 10.1007/s11239-016-1409-5, indexed in Pubmed: 27517381.
15. Driver K, Chisholm CA, Darby AE, et al. Catheter Ablation of Arrhythmia During Pregnancy. J Cardiovasc Electrophysiol. 2015; 26(6): 698–702, doi: 10.1111/jce.12675, indexed in Pubmed: 25828853.
16. Chen G, Sun Ge, Xu R, et al. Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: Two case reports and literature review. Medicine (Baltimore). 2016; 95(32): e4487, doi: 10.1097/MD.0000000000004487, indexed in Pubmed: 27512864.
17. Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2010; 21(8): 877–882, doi: 10.1111/j.1540-8167.2010.01727.x, indexed in Pubmed: 20158563.
18. Dronkers CEA, Srámek A, Huisman MV, et al. Accurate diagnosis of iliac vein thrombosis in pregnancy with magnetic resonance direct thrombus imaging (MRDTI). BMJ Case Rep. 2016; 2016, doi: 10.1136/bcr-2016-218091, indexed in Pubmed: 27965311.
19. Curry RA, Gelson E, Swan L, et al. Marfan syndrome and pregnancy: maternal and neonatal outcomes. BJOG. 2014; 121(5): 610–617, doi: 10.1111/1471-0528.12515, indexed in Pubmed: 24418012.
20. Carlson M, Airhart N, Lopez L, et al. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the international turner syndrome aortic dissection registry. Circulation. 2012; 126(18): 2220–2226, doi: 10.1161/CIRCULATIONAHA.111.088633, indexed in Pubmed: 23032325.
21. Heavner MS, Zhang M, Bast CE, et al. Thrombolysis for Massive Pulmonary Embolism in Pregnancy. Pharmacotherapy. 2017; 37(11): 1449–1457, doi: 10.1002/phar.2025, indexed in Pubmed: 28891082.
22. Leffert L, Butwick A, Carvalho B, et al. members of the SOAP VTE Taskforce. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg. 2018; 126(3): 928–944, doi: 10.1213/ANE.0000000000002530, indexed in Pubmed: 29099429.
23. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2015; 37(1): 67–119, doi: 10.1093/eurheartj/ehv317.
24. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010; 121(13): 1465–1473, doi: 10.1161/CIRCULATIONAHA.109.901496, indexed in Pubmed: 20308616.
25. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017; 38(35): 2671–2679, doi: 10.1093/eurheartj/ehx355, indexed in Pubmed: 28934837.
26. Pepin M, Schwarze U, Superti-Furga A, et al. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000; 342(10): 673–680, doi: 10.1056/NEJM200003093421001, indexed in Pubmed: 10706896.
27. Worldatlas. Countries with the oldest average mother's age at first birth. https://www worldatlas com/articles/countries-with-the-highest-mother-s-mean-age-atfirst-birth html. (25 April 2017).
28. Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367(9516): 1066–1074, doi: 10.1016/S0140-6736(06)68397-9, indexed in Pubmed: 16581405.
29. Siu SC, Sermer M, Colman JM, et al. Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104(5): 515–521, indexed in Pubmed: 11479246.
30. Swan L. Congenital heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014; 28(4): 495–506, doi: 10.1016/j.bpobgyn.2014.03.002, indexed in Pubmed: 24675221.
31. Rutherford JD. Heart failure in pregnancy. Curr Heart Fail Rep. 2012; 9(4): 277–281, doi: 10.1007/s11897-012-0105-9, indexed in Pubmed: 22821089.
32. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014; 11(6): 364–370, doi: 10.1038/nrcardio.2014.37, indexed in Pubmed: 24686946.
33. Kampman MAM, Valente MAE, van Melle JP, et al. ZAHARA II investigators. Cardiac adaption during pregnancy in women with congenital heart disease and healthy women. Heart. 2016;

102(16): 1302–1308, doi: 10.1136/heartjnl-2015-308946, indexed in Pubmed: 27048772.
34. Cornette J, Ruys TPE, Roos-Hesselink JW, et al. Hemodynamic adaptation to pregnancy in women with structural heart disease. Int J Cardiol. 2013; 168(2): 825–831, doi: 10.1016/j.ijcard.2012.10.005, indexed in Pubmed: 23151412.
35. Wald RM, Silversides CK, Kingdom J, et al. Maternal Cardiac Output and Fetal Doppler Predict Adverse Neonatal Outcomes in Pregnant Women With Heart Disease. J Am Heart Assoc. 2015; 4(11), doi: 10.1161/JAHA.115.002414, indexed in Pubmed: 26597153.
36. Pieper P. Use of medication for cardiovascular disease during pregnancy. Nature Reviews Cardiology. 2015; 12(12): 718–729, doi: 10.1038/nrcardio.2015.172.
37. Pieper P, Balci A, Aarnoudse J, et al. Uteroplacental Blood Flow, Cardiac Function, and Pregnancy Outcome in Women With Congenital Heart Disease. Circulation. 2013; 128(23): 2478–2487, doi: 10.1161/circulationaha.113.002810.
38. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005; 44(10): 989–1008, doi: 10.2165/00003088-200544100-00001, indexed in Pubmed: 16176115.
39. Roos-Hesselink JW, Budts W, Walker F, et al. Organisation of care for pregnancy in patients with congenital heart disease. Heart. 2017; 103(23): 1854–1859, doi: 10.1136/heartjnl-2017-311758, indexed in Pubmed: 28739807.
40. Ohuchi H, Tanabe Y, Kamiya C, et al. Cardiopulmonary variables during exercise predict pregnancy outcome in women with congenital heart disease. Circ J. 2013; 77(2): 470–476, indexed in Pubmed: 23059769.
41. Drenthen W, Pieper PG, Roos-Hesselink JW, et al. ZAHARA Investigators. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol. 2007; 49(24): 2303–2311, doi: 10.1016/j.jacc.2007.03.027, indexed in Pubmed: 17572244.
42. Drenthen W, Boersma E, Balci A, et al. ZAHARA Investigators. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010; 31(17): 2124–2132, doi: 10.1093/eurheartj/ehq200, indexed in Pubmed: 20584777.
43. Ruys TPE, Roos-Hesselink JW, Hall R, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart. 2014; 100(3): 231–238, doi: 10.1136/heartjnl-2013-304888, indexed in Pubmed: 24293523.
44. Balci A, Sollie-Szarynska KM, van der Bijl AGL, et al. ZAHARA-II investigators. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. 2014; 100(17): 1373–1381, doi: 10.1136/heartjnl-2014-305597, indexed in Pubmed: 25034822.
45. Cauldwell M, Patel RR, Steer PJ, et al. Managing subfertility in patients with heart disease: What are the choices? Am Heart J. 2017; 187: 29–36, doi: 10.1016/j.ahj.2017.02.007, indexed in Pubmed: 28454805.
46. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010; 56(15): 1247–1253, doi: 10.1016/j.jacc.2010.02.076, indexed in Pubmed: 20883932.
47. Kampman MAM, Balci A, van Veldhuisen DJ, et al. ZAHARA II investigators. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. Eur Heart J. 2014; 35(11): 708–715, doi: 10.1093/eurheartj/eht526, indexed in Pubmed: 24334717.
48. Song YB, Park SW, Kim JH, et al. Outcomes of pregnancy in women with congenital heart disease: a single center experience in Korea. J Korean Med Sci. 2008; 23(5): 808–813, doi: 10.3346/jkms.2008.23.5.808, indexed in Pubmed: 18955786.
49. Liu H, Huang TT, Lin JH. Risk factors and risk index of cardiac events in pregnant women with heart disease. Chin Med J (Engl). 2012; 125(19): 3410–3415, indexed in Pubmed: 23044297.
50. Ouyang DW, Khairy P, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006; 113(4): 517–524, doi: 10.1161/CIRCULATIONAHA.105.589655, indexed in Pubmed: 16449731.
51. Lindheimer M, Taler S, Cunningham F. ASH Position Paper: Hypertension in Pregnancy. The Journal of Clinical Hypertension. 2009; 11(4): 214–225, doi: 10.1111/j.1751-7176.2009.00085.x.
52. Cornette J, Ruys TPE, Roos-Hesselink JW. Assessment of the right ventricle in pregnant women with and without structural heart disease. Int J Cardiol. 2013; 168(3): 3087, doi: 10.1016/j.ijcard.2013.04.082, indexed in Pubmed: 23673202.
53. American College of Obstetricians and Gynecologists' Committee on Obstetric Practice, American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 656 Summary: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol. 2016; 127(2): 418–e80, doi: 10.1097/AOG.0000000000001309, indexed in Pubmed: 26942384.
54. Buys R, Cornelissen V, Van De Bruaene A, et al. Measures of exercise capacity in adults with congenital heart disease. Int J Cardiol. 2011; 153(1): 26–30, doi: 10.1016/j.ijcard.2010.08.030, indexed in Pubmed: 20840883.
55. Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016; 316(9): 952–961, doi: 10.1001/jama.2016.12126, indexed in Pubmed: 27599330.
56. ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004; 104(3): 647–651, indexed in Pubmed: 15339791.
57. International Commission on Radiological Protection. Pregnancy and medical radiation. ICRP publication 84. Ann ICRP 2000;30:iii–viii, 1–43.
58. Yang Bo, Ren BoXu, Tang FRu. Prenatal irradiation-induced brain neuropathology and cognitive impairment. Brain Dev. 2017; 39(1): 10–22, doi: 10.1016/j.braindev.2016.07.008, indexed in Pubmed: 27527732.
59. Boice J, Miller R. Childhood and adult cancer after intrauterine exposure to ionizing radiation. Teratology. 1999; 59(4): 227–233, doi: 10.1002/(sici)1096-9926(199904)59:4<227::aid-tera7>3.0.co;2-e.
60. Kelaranta A, Kaasalainen T, Seuri R, et al. Fetal radiation dose in computed tomography. Radiat Prot Dosimetry. 2015; 165(1-4): 226–230, doi: 10.1093/rpd/ncv097, indexed in Pubmed: 25836690.
61. Schrale RG, Ormerod J, Ormerod OJM. Percutaneous device closure of the patent foramen ovale during pregnancy. Catheter Cardiovasc Interv. 2007; 69(4): 579–583, doi: 10.1002/ccd.21031, indexed in Pubmed: 17295329.
62. Sachs HC. Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013; 132(3): e796–e809, doi: 10.1542/peds.2013-1985, indexed in Pubmed: 23979084.
63. van der Linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011; 58(21): 2241–2247, doi: 10.1016/j.jacc.2011.08.025, indexed in Pubmed: 22078432.
64. Gill HK, Splitt M, Sharland GK, et al. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol. 2003; 42(5): 923–929, indexed in Pubmed: 12957444.
65. O'Mahony C, Akhtar MM, Anastasiou Z, et al. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznawania i postepowania w kardiomiopatii przerostowej, Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733–2779, doi: 10.1093/eurheartj/ehu284, indexed in Pubmed: 25173338.
66. Charron P, Arad M, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010; 31(22): 2715–2726, doi: 10.1093/eurheartj/ehq271, indexed in Pubmed: 20823110.
67. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013; 110(4): 697–705, doi: 10.1160/TH13-01-0011, indexed in Pubmed: 23846575.

68. Pierpont M, Basson C, Benson D, et al. Genetic Basis for Congenital Heart Defects: Current Knowledge. Circulation. 2007; 115(23): 3015–3038, doi: 10.1161/circulationaha.106.183056.
69. Burchill L, Greenway S, Silversides CK, et al. Genetic counseling in the adult with congenital heart disease: what is the role? Curr Cardiol Rep. 2011; 13(4): 347–355, doi: 10.1007/s11886-011-0188-z, indexed in Pubmed: 21537992.
70. Cowan JR, Ware SM. Genetics and genetic testing in congenital heart disease. Clin Perinatol. 2015; 42(2): 373–93, ix, doi: 10.1016/j.clp.2015.02.009, indexed in Pubmed: 26042910.
71. Girerd B, Lau E, Montani D, et al. Genetics of pulmonary hypertension in the clinic. Curr Opin Pulm Med. 2017; 23(5): 386–391, doi: 10.1097/MCP.0000000000000414, indexed in Pubmed: 28661905.
72. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015; 36: 2793–2867.
73. Skirton H, Goldsmith L, Jackson L, et al. Offering prenatal diagnostic tests: European guidelines for clinical practice [corrected]. Eur J Hum Genet. 2014; 22(5): 580–586, doi: 10.1038/ejhg.2013.205, indexed in Pubmed: 24022298.
74. Alanen J, Leskinen M, Sairanen M, et al. Fetal nuchal translucency in severe congenital heart defects: experiences in Northern Finland. J Matern Fetal Neonatal Med. 2017 [Epub ahead of print]: 1–7, doi: 10.1080/14767058.2017.1408067, indexed in Pubmed: 29157037.
75. Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ. 1999; 318(7176): 81–85, indexed in Pubmed: 9880278.
76. Rasiah SV, Publicover M, Ewer AK, et al. A systematic review of the accuracy of first-trimester ultrasound examination for detecting major congenital heart disease. Ultrasound Obstet Gynecol. 2006; 28(1): 110–116, doi: 10.1002/uog.2803, indexed in Pubmed: 16795132.
77. Eleftheriades M, Tsapakis E, Sotiriadis A, et al. Detection of congenital heart defects throughout pregnancy; impact of first trimester ultrasound screening for cardiac abnormalities. J Matern Fetal Neonatal Med. 2012; 25(12): 2546–2550, doi: 10.3109/14767058.2012.703716, indexed in Pubmed: 22712625.
78. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart. 2003; 89(7): 752–756, indexed in Pubmed: 12807849.
79. Rychik J, Ayres N, Cuneo B, et al. American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram. J Am Soc Echocardiogr. 2004; 17(7): 803–810, doi: 10.1016/j.echo.2004.04.011, indexed in Pubmed: 15220910.
80. Fetal Echocardiography Task Force, American Institute of Ultrasound in Medicine Clinical Standards Committee, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. AIUM practice guideline for the performance of fetal echocardiography. J Ultrasound Med. 2011; 30(1): 127–136, indexed in Pubmed: 21193716.
81. Alfirevic Z, Neilson JP, Neilson JP, et al. Doppler ultrasound for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev. 2000(2): CD000073, doi: 10.1002/14651858.CD000073, indexed in Pubmed: 10796113.
82. Manning F. FETAL BIOPHYSICAL PROFILE. Obstetrics and Gynecology Clinics of North America. 1999; 26(4): 557–577, doi: 10.1016/s0889-8545(05)70099-1.
83. Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. TRUFFLE study group. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385(9983): 2162–2172, doi: 10.1016/S0140-6736(14)62049-3, indexed in Pubmed: 25747582.
84. Wieseler KM, Bhargava P, Kanal KM, et al. Imaging in pregnant patients: examination appropriateness. Radiographics. 2010; 30(5): 1215–29; discussion 1230, doi: 10.1148/rg.305105034, indexed in Pubmed: 20833847.
85. Ntusi NA, Samuels P, Moosa S, et al. Diagnosing cardiac disease during pregnancy: imaging modalities. Cardiovasc J Afr. 2016; 27(2): 95–103, doi: 10.5830/CVJA-2016-022, indexed in Pubmed: 27213857.
86. Kapoor MC. Cardiopulmonary bypass in pregnancy. Ann Card Anaesth. 2014; 17(1): 33–39, doi: 10.4103/0971-9784.124133, indexed in Pubmed: 24401299.
87. Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol. 2007; 109(2 Pt 1): 253–261, doi: 10.1097/01.AOG.0000253215.79121.75, indexed in Pubmed: 17267821.
88. John AS, Gurley F, Schaff HV, et al. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg. 2011; 91(4): 1191–1196, doi: 10.1016/j.athoracsur.2010.11.037, indexed in Pubmed: 21440145.
89. Chandrasekhar S, Cook CR, Collard CD. Cardiac surgery in the parturient. Anesth Analg. 2009; 108(3): 777–785, doi: 10.1213/ane.0b013e31819367aa, indexed in Pubmed: 19224782.
90. Hosseini S, Kashfi F, Samiei N, et al. Feto-maternal outcomes of urgent open-heart surgery during pregnancy. J Heart Valve Dis. 2015; 24(2): 253–259, indexed in Pubmed: 26204695.
91. Mishanina E, Rogozinska E, Thatthi T, et al. Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis. CMAJ. 2014; 186(9): 665–673, doi: 10.1503/cmaj.130925, indexed in Pubmed: 24778358.
92. Salam AM, Ertekin E, van Hagen IM, et al. ROPAC Investigators. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. 2013; 34(9): 657–665, doi: 10.1093/eurheartj/ehs270, indexed in Pubmed: 22968232.
93. Ramsey PS, Hogg BB, Savage KG, et al. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol. 2000; 183(5): 1100–1102, doi: 10.1067/mob.2000.108886, indexed in Pubmed: 11084548.
94. Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of prostaglandin E2. Anaesthesia. 1990; 45(10): 848–849, indexed in Pubmed: 2240500.
95. Perloff JK, Child J. Congenital heart disease in adults. 2nd ed. Philadelphia: WB Saunders; 1998.
96. Ruys TPE, Roos-Hesselink JW, Pijuan-Domènech A, et al. ROPAC investigators. Is a planned caesarean section in women with cardiac disease beneficial? Heart. 2015; 101(7): 530–536, doi: 10.1136/heartjnl-2014-306497, indexed in Pubmed: 25539946.
97. van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis. 2011; 22(7): 565–570, doi: 10.1097/MBC.0b013e3283494b3c, indexed in Pubmed: 21959588.
98. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006; 118(3): 313–320, doi: 10.1016/j.thromres.2005.08.005, indexed in Pubmed: 16182346.
99. Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016; 116(5): 879–890, doi: 10.1160/TH16-04-0266, indexed in Pubmed: 27488143.
100. Devitt JH, Noble WH, Byrick RJ. A Swan-Ganz catheter related complication in a patient with Eisenmenger's syndrome. Anesthesiology. 1982; 57(4): 335–337, indexed in Pubmed: 7125276.
101. Dob DP, Yentis SM. Practical management of the parturient with congenital heart disease. Int J Obstet Anesth. 2006; 15(2): 137–144, doi: 10.1016/j.ijoa.2005.07.005, indexed in Pubmed: 16434181.
102. Rossi A, Cornette J, Johnson MR, et al. Quantitative cardiovascular magnetic resonance in pregnant women: cross-sectional analysis of physiological parameters throughout pregnancy and the impact of the supine position. J Cardiovasc Magn Reson. 2011; 13: 31, doi: 10.1186/1532-429X-13-31, indexed in Pubmed: 21708015.
103. Blake MJ, Martin A, Manktelow BN, et al. Changes in baroreceptor sensitivity for heart rate during normotensive pregnancy and the puerperium. Clin Sci (Lond). 2000; 98(3): 259–268, indexed in Pubmed: 10677383.
104. Foley M, Lockwood C, Gersh B, Barss V. Maternal cardiovascular and hemodynamic adaptation to pregnancy. https://www.scribd.com/document/269648347/Maternal-Cardiovascular-and-Hemodynamic-Adaptations-to-Pregnancy 2010.
105. Cauldwell M, Steer P, Swan L, et al. The management of the third stage of labour in women with heart disease. Heart. 2016; 103(12): 945–951, doi: 10.1136/heartjnl-2016-310607.
106. Hofmeyr GJ, Gülmezoglu AM, Novikova N, et al. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull

World Health Organ. 2009; 87(9): 666–677, indexed in Pubmed: 19784446.
107. de Labriolle A, Genée O, Heggs LM, et al. Acute myocardial infarction following oral methyl-ergometrine intake. Cardiovasc Toxicol. 2009; 9(1): 46–48, doi: 10.1007/s12012-009-9031-9, indexed in Pubmed: 19219407.
108. Svanström MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008; 100(5): 683–689, doi: 10.1093/bja/aen071, indexed in Pubmed: 18385263.
109. Bateman BT, Patorno E, Desai RJ, et al. Late Pregnancy Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics. 2016; 138(3), doi: 10.1542/peds.2016-0731, indexed in Pubmed: 27577580.
110. Kuijpers JM, Koolbergen DR, Groenink M, et al. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: focus on the use of prosthetic material. Eur Heart J. 2017; 38(26): 2048–2056, doi: 10.1093/eurheartj/ehw591, indexed in Pubmed: 28065906.
111. Kebed KY, Bishu K, Al Adham RI, et al. Pregnancy and postpartum infective endocarditis: a systematic review. Mayo Clin Proc. 2014; 89(8): 1143–1152, doi: 10.1016/j.mayocp.2014.04.024, indexed in Pubmed: 24997091.
112. Habib G, Lancellotti P, Iung B, et al. Task Force per il Trattamento dell'Endocardite Infettiva della Società Europea di Cardiologia (ESC), ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36(44): 3075–3128, doi: 10.1093/eurheartj/ehv319, indexed in Pubmed: 26320109.
113. Montoya ME, Karnath BM, Ahmad M. Endocarditis during pregnancy. South Med J. 2003; 96(11): 1156–1157, doi: 10.1097/01.SMJ.0000054503.18393.1E, indexed in Pubmed: 14632369.
114. Campuzano K, Roqué H, Bolnick A, et al. Bacterial endocarditis complicating pregnancy: case report and systematic review of the literature. Arch Gynecol Obstet. 2003; 268(4): 251–255, doi: 10.1007/s00404-003-0485-x, indexed in Pubmed: 12728325.
115. Drugs.com. FDA Pregnancy Categories. https://www.drugs.com/pregnancy/.
116. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006; 32(2): 75–81, doi: 10.1783/147118906776276486, indexed in Pubmed: 16824295.
117. World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO Press; 2015. p.267.
118. Mercer C, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet. 2013; 382(9907): 1781–1794, doi: 10.1016/s0140-6736(13)62035-8.
119. Kaemmerer M, Vigl M, Seifert-Klauss V, et al. Sexuality and reproductive health in women with congenital heart disease. Am J Cardiol. 2010; 105(4): 538–541, doi: 10.1016/j.amjcard.2009.10.025, indexed in Pubmed: 20152251.
120. Roos-Hesselink JW, Cornette J, Sliwa K, et al. Contraception and cardiovascular disease. Eur Heart J. 2015; 36(27): 1728–34, 1734a, doi: 10.1093/eurheartj/ehv141, indexed in Pubmed: 25926560.
121. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339: b2890, doi: 10.1136/bmj.b2890, indexed in Pubmed: 19679613.
122. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 366(24): 2257–2266, doi: 10.1056/NEJMoa1111840, indexed in Pubmed: 22693997.
123. Vieira CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod. 2007; 22(8): 2196–2201, doi: 10.1093/humrep/dem153, indexed in Pubmed: 17569674.
124. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev. 2012(8): CD001324, doi: 10.1002/14651858.CD001324.pub4, indexed in Pubmed: 22895920.
125. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 1999; 59(2): 79–83, indexed in Pubmed: 10361621.
126. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol. 2013; 29 Suppl 1: 1–14, doi: 10.3109/09513590.2013.774591, indexed in Pubmed: 23437846.
127. Jesam C, Cochon L, Salvatierra AM, et al. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception. 2016; 93(4): 310–316, doi: 10.1016/j.contraception.2015.12.015, indexed in Pubmed: 26764121.
128. Valle RF, Carignan CS, Wright TC, et al. STOP Prehysterectomy Investigation Group. Tissue response to the STOP microcoil transcervical permanent contraceptive device: results from a prehysterectomy study. Fertil Steril. 2001; 76(5): 974–980, indexed in Pubmed: 11704120.
129. Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. Obstet Gynecol. 2015; 126(1): 22–28, doi: 10.1097/AOG.0000000000000910, indexed in Pubmed: 26241252.
130. Dhalwani NN, Fiaschi L, West J, et al. Occurrence of fertility problems presenting to primary care: population-level estimates of clinical burden and socioeconomic inequalities across the UK. Hum Reprod. 2013; 28(4): 960–968, doi: 10.1093/humrep/des451, indexed in Pubmed: 23315065.
131. Humaidan P, Nelson SM, Devroey P, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016; 31(9): 1997–2004, doi: 10.1093/humrep/dew149, indexed in Pubmed: 27343272.
132. Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol. 2003; 102(4): 806–815, indexed in Pubmed: 14551012.
133. Ombelet W, Martens G, De Sutter P, et al. Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. Hum Reprod. 2006; 21(4): 1025–1032, doi: 10.1093/humrep/dei419, indexed in Pubmed: 16339165.
134. Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality. Royal College of Obstetricians and Gynaecologists Green-Top Guideline No. 7. October 2010. London: Royal College of Obstetricians and Gynaecologists; 2015.
135. Lees C, Marlow N, Arabin B, et al. TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42(4): 400–408, doi: 10.1002/uog.13190, indexed in Pubmed: 24078432.
136. Marelli AJ, Ionescu-Ittu R, Mackie AS, et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014; 130(9): 749–756, doi: 10.1161/CIRCULATIONAHA.113.008396, indexed in Pubmed: 24944314.
137. Mandalenakis Z, Rosengren A, Skoglund K, et al. Survivorship in Children and Young Adults With Congenital Heart Disease in Sweden. JAMA Intern Med. 2017; 177(2): 224–230, doi: 10.1001/jamainternmed.2016.7765, indexed in Pubmed: 27992621.
138. Sliwa K, van Hagen IM, Budts W, et al. ROPAC investigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016; 18(9): 1119–1128, doi: 10.1002/ejhf.594, indexed in Pubmed: 27384461.
139. Balint OH, Siu SC, Mason J, et al. Cardiac outcomes after pregnancy in women with congenital heart disease. Heart. 2010; 96(20): 1656–1661, doi: 10.1136/hrt.2010.202838, indexed in Pubmed: 20937754.
140. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1): 104–109, doi: 10.1183/09031936.00092306, indexed in Pubmed: 17360728.
141. Bendayan D, Hod M, Oron G, et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol. 2005; 106(5 Pt 2): 1206–1210, doi: 10.1097/01.AOG.0000164074.64137.f1, indexed in Pubmed: 16260574.
142. Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012; 40(4): 881–885, doi: 10.1183/09031936.00141211, indexed in Pubmed: 22282544.

143. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013; 143(5): 1330–1336, doi: 10.1378/chest.12-0528, indexed in Pubmed: 23100080.
144. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009; 30(3): 256–265, doi: 10.1093/eurheartj/ehn597, indexed in Pubmed: 19147605.
145. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015; 5(3): 435–465, doi: 10.1086/682230, indexed in Pubmed: 26401246.
146. Duan R, Xu X, Wang X, et al. Pregnancy outcome in women with Eisenmenger's syndrome: a case series from west China. BMC Pregnancy Childbirth. 2016; 16(1): 356, doi: 10.1186/s12884-016-1153-z, indexed in Pubmed: 27852228.
147. Cha KS, Cho KIm, Seo JS, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013; 112(11): 1834–1839, doi: 10.1016/j.amjcard.2013.08.003, indexed in Pubmed: 24012036.
148. Ladouceur M, Benoit L, Basquin A, et al. How Pregnancy Impacts Adult Cyanotic Congenital Heart Disease: A Multicenter Observational Study. Circulation. 2017; 135(24): 2444–2447, doi: 10.1161/CIRCULATIONAHA.116.027152, indexed in Pubmed: 28606952.
149. Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation. 1994; 89(6): 2673–2676, indexed in Pubmed: 8205680.
150. Yap SC, Drenthen W, Meijboom FJ, et al. ZAHARA investigators. Comparison of pregnancy outcomes in women with repaired versus unrepaired atrial septal defect. BJOG. 2009; 116(12): 1593–1601, doi: 10.1111/j.1471-0528.2009.02301.x, indexed in Pubmed: 19681849.
151. Balci A, Drenthen W, Mulder BJM, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart J. 2011; 161(2): 307–313, doi: 10.1016/j.ahj.2010.10.027, indexed in Pubmed: 21315213.
152. Kampman MAM, Siegmund AS, Bilardo CM, et al. ZAHARA investigators. Uteroplacental Doppler flow and pregnancy outcome in women with tetralogy of Fallot. Ultrasound Obstet Gynecol. 2017; 49(2): 231–239, doi: 10.1002/uog.15938, indexed in Pubmed: 27071979.
153. Lima FV, Koutrolou-Sotiropoulou P, Yen TY, et al. Clinical characteristics and outcomes in pregnant women with Ebstein anomaly at the time of delivery in the USA: 2003-2012. Arch Cardiovasc Dis. 2016; 109(6-7): 390–398, doi: 10.1016/j.acvd.2016.01.010, indexed in Pubmed: 27079467.
154. Bowater SE, Selman TJ, Hudsmith LE, et al. Long-term outcome following pregnancy in women with a systemic right ventricle: is the deterioration due to pregnancy or a consequence of time? Congenit Heart Dis. 2013; 8(4): 302–307, doi: 10.1111/chd.12001, indexed in Pubmed: 22967110.
155. Cataldo S, Doohan M, Rice K, et al. Pregnancy following Mustard or Senning correction of transposition of the great arteries: a retrospective study. BJOG. 2016; 123(5): 807–813, doi: 10.1111/1471-0528.13508, indexed in Pubmed: 26138245.
156. Hornung T, Bernard E, Celermajer D, et al. Right ventricular dysfunction in congenitally corrected transposition of the great arteries. The American Journal of Cardiology. 1999; 84(9): 1116–1119, doi: 10.1016/s0002-9149(99)00516-0.
157. Gouton M, Nizard J, Patel M, et al. Maternal and fetal outcomes of pregnancy with Fontan circulation: A multicentric observational study. Int J Cardiol. 2015; 187: 84–89, doi: 10.1016/j.ijcard.2015.03.344, indexed in Pubmed: 25828319.
158. Cauldwell M, Von Klemperer K, Uebing A, et al. Why is post-partum haemorrhage more common in women with congenital heart disease? Int J Cardiol. 2016; 218: 285–290, doi: 10.1016/j.ijcard.2016.05.068, indexed in Pubmed: 27240153.
159. Zentner D, Kotevski A, King I, et al. Fertility and pregnancy in the Fontan population. Int J Cardiol. 2016; 208: 97–101, doi: 10.1016/j.ijcard.2016.01.180, indexed in Pubmed: 26836494.
160. Niwa K, Siu SC, Webb GD, et al. Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation. 2002; 106(11): 1374–1378, indexed in Pubmed: 12221055.
161. Sawlani N, Shroff A, Vidovich MI. Aortic dissection and mortality associated with pregnancy in the United States. J Am Coll Cardiol. 2015; 65(15): 1600–1601, doi: 10.1016/j.jacc.2014.12.066, indexed in Pubmed: 25881947.
162. Thalmann M, Sodeck GH, Domanovits H, et al. Acute type A aortic dissection and pregnancy: a population-based study. Eur J Cardiothorac Surg. 2011; 39(6): e159–e163, doi: 10.1016/j.ejcts.2010.12.070, indexed in Pubmed: 21353789.
163. Hiratzka L, Bakris G, Beckman J, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Circulation. 2010; 121(13), doi: 10.1161/cir.0b013e3181d4739e.
164. Erbel R, Aboyans V, Boileau C, et al. Authors/Task Force members, Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznawania i leczenia chorób aorty, ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(41): 2873–2926, doi: 10.1093/eurheartj/ehu281, indexed in Pubmed: 25173340.
165. Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol. 1967; 83(4): 336–341, indexed in Pubmed: 4225694.
166. Gutin LS, Merz AE, Bakalov VK, et al. Parity and aortic dimensions in healthy women. Int J Cardiol. 2013; 165(2): 383–384, doi: 10.1016/j.ijcard.2012.08.022, indexed in Pubmed: 22999343.
167. Meijboom LJ, Vos FE, Timmermans J, et al. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J. 2005; 26(9): 914–920, doi: 10.1093/eurheartj/ehi103, indexed in Pubmed: 15681576.
168. Donnelly RT, Pinto NM, Kocolas I, et al. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol. 2012; 60(3): 224–229, doi: 10.1016/j.jacc.2012.03.051, indexed in Pubmed: 22789886.
169. Januzzi JL, Isselbacher EM, Fattori R, et al. International Registry of Aortic Dissection (IRAD). Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol. 2004; 43(4): 665–669, doi: 10.1016/j.jacc.2003.08.054, indexed in Pubmed: 14975480.
170. Smith K, Gros B. Pregnancy-related acute aortic dissection in Marfan syndrome: A review of the literature. Congenit Heart Dis. 2017; 12(3): 251–260, doi: 10.1111/chd.12465, indexed in Pubmed: 28371362.
171. Pyeritz R. Maternal and fetal complications of pregnancy in the Marfan syndrome. The American Journal of Medicine. 1981; 71(5): 784–790, doi: 10.1016/0002-9343(81)90365-x.
172. Sayama S, Takeda N, Iriyama T, et al. Peripartum type B aortic dissection in patients with Marfan syndrome who underwent aortic root replacement: a case series study. BJOG. 2018; 125(4): 487–493, doi: 10.1111/1471-0528.14635, indexed in Pubmed: 28294527.
173. Rossiter JP, Repke JT, Morales AJ, et al. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol. 1995; 173(5): 1599–1606, indexed in Pubmed: 7503207.
174. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47(7): 476–485, doi: 10.1136/jmg.2009.072785, indexed in Pubmed: 20591885.
175. Goland S, Elkayam U. Cardiovascular problems in pregnant women with marfan syndrome. Circulation. 2009; 119(4): 619–623, doi: 10.1161/CIRCULATIONAHA.104.493569, indexed in Pubmed: 19188522.
176. McKellar SH, MacDonald RJ, Michelena HI, et al. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. Am J Cardiol. 2011; 107(1): 96–99, doi: 10.1016/j.amjcard.2010.08.061, indexed in Pubmed: 21146694.
177. Murray ML, Pepin M, Peterson S, et al. Pregnancy-related deaths and complications in women with vascular Ehlers-Danlos syndrome. Genet Med. 2014; 16(12): 874–880, doi: 10.1038/gim.2014.53, indexed in Pubmed: 24922461.
178. Gravholt CH, Andersen NH, Conway GS, et al. International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from

the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017; 177(3): G1–G70, doi: 10.1530/EJE-17-0430, indexed in Pubmed: 28705803.
179. Carlson M, Silberbach M, Carlson M, et al. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet. 2007; 44(12): 745–749, doi: 10.1136/jmg.2007.052019, indexed in Pubmed: 17873120.
180. Gravholt CH, Landin-Wilhelmsen K, Stochholm K, et al. Clinical and epidemiological description of aortic dissection in Turner's syndrome. Cardiol Young. 2006; 16(5): 430–436, doi: 10.1017/S1047951106000928, indexed in Pubmed: 16984695.
181. Regalado ES, Guo Dc, Estrera AL, et al. Acute aortic dissections with pregnancy in women with ACTA2 mutations. Am J Med Genet A. 2014; 164A(1): 106–112, doi: 10.1002/ajmg.a.36208, indexed in Pubmed: 24243736.
182. van Hagen IM, van der Linde D, van de Laar IM, et al. Pregnancy in Women With SMAD3 Mutation. J Am Coll Cardiol. 2017; 69(10): 1356–1358, doi: 10.1016/j.jacc.2016.12.029, indexed in Pubmed: 28279300.
183. Braverman AC, Moon MR, Geraghty P, et al. Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection. Am J Med Genet A. 2016; 170(8): 2177–2180, doi: 10.1002/ajmg.a.37694, indexed in Pubmed: 27125181.
184. Jondeau G, Ropers J, Regalado E, et al. Montalcino Aortic Consortium. International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016; 9(6): 548–558, doi: 10.1161/CIRCGENETICS.116.001485, indexed in Pubmed: 27879313.
185. Whelton PK, Carey RM, Aronow WS, et al. Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Sr., Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/aASH/ASPC/NMA/ /PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Cinical Practice Guidelines. Hypertension. 2018; 71: e13–e115.
186. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010; 376(9751): 1476–1484, doi: 10.1016/S0140-6736(10)60960-9, indexed in Pubmed: 20825986.
187. Yates MT, Soppa G, Smelt J, et al. Perioperative management and outcomes of aortic surgery during pregnancy. J Thorac Cardiovasc Surg. 2015; 149(2): 607–610, doi: 10.1016/j.jtcvs.2014.10.038, indexed in Pubmed: 25524653.
188. Suzuki T, Isselbacher EM, Nienaber CA, et al. IRAD Investigators. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012; 109(1): 122–127, doi: 10.1016/j.amjcard.2011.08.012, indexed in Pubmed: 21944678.
189. Fattori R, Montgomery D, Lovato L, et al. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc Interv. 2013; 6(8): 876–882, doi: 10.1016/j.jcin.2013.05.003, indexed in Pubmed: 23968705.
190. Brener MI, Keramati AR. Type B Dissection in a Pregnant Woman Managed With Peripartum Thoracic Endovascular Aortic Repair. Circulation. 2016; 133(5): e369–e373, doi: 10.1161/CIRCULATIONAHA.115.019735, indexed in Pubmed: 26831438.
191. De Martino RR, Johnstone J, Baldwin EA, et al. Endograft as Bridge to Open Repair for Ruptured Thoracic Aneurysm in a Pregnant Marfan Patient. Ann Thorac Surg. 2015; 100(1): 304–307, doi: 10.1016/j.athoracsur.2014.09.073, indexed in Pubmed: 26140774.
192. Liu H, Shu C, Li X, et al. Endovascular aortic repair combined with chimney technique in the treatment of stanford type B aortic dissection involving aortic arch. Ann Vasc Surg. 2015; 29(4): 758–763, doi: 10.1016/j.avsg.2014.12.004, indexed in Pubmed: 25722251.
193. Chahwala V, Tashiro J, Baqai A, et al. Endovascular repair of a thoracic aortic aneurysm in pregnancy at 22 weeks of gestation. J Vasc Surg. 2015; 62(5): 1323–1325, doi: 10.1016/j.jvs.2014.04.037, indexed in Pubmed: 24863183.
194. Leśniak-Sobelga A, Tracz W, KostKiewicz M, et al. Clinical and echocardiographic assessment of pregnant women with valvular heart diseases--maternal and fetal outcome. Int J Cardiol. 2004; 94(1): 15–23, doi: 10.1016/j.ijcard.2003.03.017, indexed in Pubmed: 14996469.
195. Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015; 36(18): 1115–22a, doi: 10.1093/eurheartj/ehu449, indexed in Pubmed: 25425448.
196. van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. ROPAC Investigators and the EURObservational Research Programme (EORP) Team*. Pregnancy in Women With a Mechanical Heart Valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015; 132(2): 132–142, doi: 10.1161/CIRCULATIONAHA.115.015242, indexed in Pubmed: 26100109.
197. Samiei N, Amirsardari M, Rezaei Y, et al. Echocardiographic Evaluation of Hemodynamic Changes in Left-Sided Heart Valves in Pregnant Women With Valvular Heart Disease. Am J Cardiol. 2016; 118(7): 1046–1052, doi: 10.1016/j.amjcard.2016.07.005, indexed in Pubmed: 27506332.
198. Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol. 2001; 37(3): 893–899, indexed in Pubmed: 11693767.
199. van Hagen IM, Thorne SA, Taha N, et al. ROPAC Investigators and EORP Team. Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease. Circulation. 2018; 137(8): 806–816, doi: 10.1161/CIRCULATIONAHA.117.032561, indexed in Pubmed: 29459466.
200. Silversides CK, Colman JM, Sermer M, et al. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol. 2003; 91(11): 1382–1385, indexed in Pubmed: 12767443.
201. Avila WS, Rossi EG, Ramires JA, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol. 2003; 26(3): 135–142, indexed in Pubmed: 12685620.
202. Diao M, Kane A, Ndiaye MB, et al. Pregnancy in women with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis. 2011; 104(6-7): 370–374, doi: 10.1016/j.acvd.2011.04.001, indexed in Pubmed: 21798468.
203. Ahmed N, Kausar H, Ali L, et al. Fetomaternal outcome of pregnancy with Mitral stenosis. Pak J Med Sci. 2015; 31(3): 643–647, doi: 10.12669/pjms.313.7020, indexed in Pubmed: 26150860.
204. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791, doi: 10.1093/eurheartj/ehx391, indexed in Pubmed: 28886619.
205. Baumgartner H, Hung J, Bermejo J, et al. American Society of Echocardiography, European Association of Echocardiography, EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009; 10(1): 1–25, doi: 10.1093/ejechocard/jen303, indexed in Pubmed: 19065003.
206. Elassy SMR, Elmidany AA, Elbawab HY. Urgent cardiac surgery during pregnancy: a continuous challenge. Ann Thorac Surg. 2014; 97(5): 1624–1629, doi: 10.1016/j.athoracsur.2013.10.067, indexed in Pubmed: 24630768.
207. Orwat S, Diller GP, van Hagen IM, et al. ROPAC Investigators. Risk of Pregnancy in Moderate and Severe Aortic Stenosis: From the Multinational ROPAC Registry. J Am Coll Cardiol. 2016; 68(16): 1727–1737, doi: 10.1016/j.jacc.2016.07.750, indexed in Pubmed: 27737738.
208. Tzemos N, Silversides CK, Colman JM, et al. Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis. Am J Cardiol. 2003; 91(11): 1386–1389, indexed in Pubmed: 12767444.
209. Yap SC, Drenthen W, Pieper PG, et al. ZAHARA investigators. Risk of complications during pregnancy in women with congenital aortic stenosis. Int J Cardiol. 2008; 126(2): 240–246, doi: 10.1016/j.ijcard.2007.03.134, indexed in Pubmed: 17482293.
210. Tzemos N, Silversides CK, Colman JM, et al. Late cardiac outcomes after pregnancy in women with congenital aortic stenosis. Am Heart J. 2009; 157(3): 474–480, doi: 10.1016/j.ahj.2008.10.020, indexed in Pubmed: 19249417.

211. Heuvelman HJ, Arabkhani B, Cornette JMJ, et al. Pregnancy outcomes in women with aortic valve substitutes. Am J Cardiol. 2013; 111(3): 382–387, doi: 10.1016/j.amjcard.2012.09.035, indexed in Pubmed: 23174182.
212. Lawley CM, Lain SJ, Algert CS, et al. Prosthetic heart valves in pregnancy, outcomes for women and their babies: a systematic review and meta-analysis. BJOG. 2015; 122(11): 1446–1455, doi: 10.1111/1471-0528.13491, indexed in Pubmed: 26119028.
213. Yap SC, Drenthen W, Pieper PG, et al. ZAHARA investigators. Outcome of pregnancy in women after pulmonary autograft valve replacement for congenital aortic valve disease. J Heart Valve Dis. 2007; 16(4): 398–403, indexed in Pubmed: 17702365.
214. Vause S, Clarke B, Tower CL, et al. (on behalf of UKOSS). Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system. BJOG. 2017; 124(9): 1411–1419, doi: 10.1111/1471-0528.14478, indexed in Pubmed: 28019065.
215. Abildgaard U, Sandset PM, Hammerstrøm J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res. 2009; 124(3): 262–267, doi: 10.1016/j.thromres.2008.12.005, indexed in Pubmed: 19162303.
216. Sillesen M, Hjortdal V, Vejlstrup N, et al. Pregnancy with prosthetic heart valves - 30 years' nationwide experience in Denmark. Eur J Cardiothorac Surg. 2011; 40(2): 448–454, doi: 10.1016/j.ejcts.2010.12.011, indexed in Pubmed: 21277217.
217. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014; 18(6): 797–806, doi: 10.1093/icvts/ivu009, indexed in Pubmed: 24595247.
218. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000; 160(2): 191–196, indexed in Pubmed: 10647757.
219. Xu Z, Fan J, Luo X, et al. Anticoagulation Regimens During Pregnancy in Patients With Mechanical Heart Valves: A Systematic Review and Meta-analysis. Can J Cardiol. 2016; 32(10): 1248.e1–1248.e9, doi: 10.1016/j.cjca.2015.11.005, indexed in Pubmed: 26927861.
220. Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol. 2009; 104(9): 1259–1263, doi: 10.1016/j.amjcard.2009.06.040, indexed in Pubmed: 19840573.
221. Quinn J, Von Klemperer K, Brooks R, et al. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica. 2009; 94(11): 1608–1612, doi: 10.3324/haematol.2008.002840, indexed in Pubmed: 19880782.
222. Basude S, Hein C, Curtis SL, et al. Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study. BJOG. 2012; 119(8): 1008–13; discussion 1012, doi: 10.1111/j.1471-0528.2012.03359.x, indexed in Pubmed: 22568528.
223. D'Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017; 38(19): 1509–1516, doi: 10.1093/eurheartj/ehx032, indexed in Pubmed: 28329059.
224. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004; 191(3): 1024–1029, doi: 10.1016/j.ajog.2004.05.050, indexed in Pubmed: 15467584.
225. Goland S, Schwartzenberg S, Fan J, et al. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels? J Cardiovasc Pharmacol Ther. 2014; 19(5): 451–456, doi: 10.1177/1074248414524302, indexed in Pubmed: 24607762.
226. Vijayan V, Rachel T. Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy. Med J Malaysia. 2012; 67(6): 591–594, indexed in Pubmed: 23770951.
227. McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. Best Pract Res Clin Obstet Gynaecol. 2014; 28(4): 519–536, doi: 10.1016/j.bpobgyn.2014.03.001, indexed in Pubmed: 24814194.
228. van Driel D, Wesseling J, Sauer PJJ, et al. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002; 66(3): 127–140, doi: 10.1002/tera.10054, indexed in Pubmed: 12210474.
229. Wesseling J, Driel D, Heymans H, et al. Coumarins during Pregnancy: Long-term Effects on Growth and Development of School-age Children. Thrombosis and Haemostasis. 2017; 85(04): 609–613, doi: 10.1055/s-0037-1615641.
230. van Driel D, Wesseling J, Sauer PJ, et al. In utero exposure to coumarins and cognition at 8 to 14 years old. Pediatrics. 2001; 107(1): 123–129, indexed in Pubmed: 11134445.
231. Özkan M, Çakal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013; 128(5): 532–540, doi: 10.1161/CIRCULATIONAHA.113.001145, indexed in Pubmed: 23812180.
232. Petitti DB, Sidney S, Quesenberry CP, et al. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke. 1997; 28(2): 280–283, indexed in Pubmed: 9040675.
233. Ladner HE, Danielsen B, Gilbert WM. Acute myocardial infarction in pregnancy and the puerperium: a population-based study. Obstet Gynecol. 2005; 105(3): 480–484, doi: 10.1097/01.AOG.0000151998.50852.31, indexed in Pubmed: 15738011.
234. James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation. 2006; 113(12): 1564–1571, doi: 10.1161/CIRCULATIONAHA.105.576751, indexed in Pubmed: 16534011.
235. Bush N, Nelson-Piercy C, Spark P, et al. UKOSS. Myocardial infarction in pregnancy and postpartum in the UK. Eur J Prev Cardiol. 2013; 20(1): 12–20, doi: 10.1177/1741826711432117, indexed in Pubmed: 22127355.
236. Berg CJ, Callaghan WM, Henderson Z, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010; 116(6): 1302–1309, doi: 10.1097/AOG.0b013e3181fdfb11, indexed in Pubmed: 21099595.
237. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008; 52(3): 171–180, doi: 10.1016/j.jacc.2008.03.049, indexed in Pubmed: 18617065.
238. Lameijer H, Kampman MAM, Oudijk MA, et al. Ischaemic heart disease during pregnancy or post-partum: systematic review and case series. Neth Heart J. 2015; 23(5): 249–257, doi: 10.1007/s12471-015-0677-6, indexed in Pubmed: 25911007.
239. Elkayam U, Jalnapurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation. 2014; 129(16): 1695–1702, doi: 10.1161/CIRCULATIONAHA.113.002054, indexed in Pubmed: 24753549.
240. Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009; 95(8): 680–686, doi: 10.1136/hrt.2008.148932, indexed in Pubmed: 19329725.
241. Tweet MS, Hayes SN, Codsi E, et al. Spontaneous Coronary Artery Dissection Associated With Pregnancy. J Am Coll Cardiol. 2017; 70(4): 426–435, doi: 10.1016/j.jacc.2017.05.055, indexed in Pubmed: 28728686.
242. Vijayaraghavan R, Verma S, Gupta N, et al. Pregnancy-related spontaneous coronary artery dissection. Circulation. 2014; 130(21): 1915–1920, doi: 10.1161/CIRCULATIONAHA.114.011422, indexed in Pubmed: 25403597.
243. Saw J, Ricci D, Starovoytov A, et al. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. JACC Cardiovasc Interv. 2013; 6(1): 44–52, doi: 10.1016/j.jcin.2012.08.017, indexed in Pubmed: 23266235.
244. Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. 2014; 7(5): 645–655, doi: 10.1161/CIRCINTERVENTIONS.114.001760, indexed in Pubmed: 25294399.
245. Agewall S, Beltrame JF, Reynolds HR, et al. WG on Cardiovascular Pharmacotherapy. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153, doi: 10.1093/eurheartj/ehw149, indexed in Pubmed: 28158518.

246. Alfonso F, Paulo M, Lennie V, et al. Spontaneous coronary artery dissection: long-term follow-up of a large series of patients prospectively managed with a. JACC Cardiovasc Interv. 2012; 5(10): 1062–1070, doi: 10.1016/j.jcin.2012.06.014, indexed in Pubmed: 23078737.
247. Tweet MS, Gulati R, Williamson EE, et al. Multimodality Imaging for Spontaneous Coronary Artery Dissection in Women. JACC Cardiovasc Imaging. 2016; 9(4): 436–450, doi: 10.1016/j.jcmg.2016.01.009, indexed in Pubmed: 27056163.
248. Goland S, Elkayam U. Anticoagulation in pregnancy. Cardiol Clin. 2012; 30(3): 395–405, doi: 10.1016/j.ccl.2012.05.003, indexed in Pubmed: 22813365.
249. Gordon CT, Jimenez-Fernandez S, Daniels LB, et al. Pregnancy in women with a history of Kawasaki disease: management and outcomes. BJOG. 2014; 121(11): 1431–1438, doi: 10.1111/1471-0528.12685, indexed in Pubmed: 24597833.
250. White HD, Thygesen K, Alpert JS, et al. Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction, Authors/Task Force Members Chairpersons, Biomarker Subcommittee, ECG Subcommittee, Imaging Subcommittee, Classification Subcommittee, Intervention Subcommittee, Trials & Registries Subcommittee, Trials & Registries Subcommittee, Trials & Registries Subcommittee, Trials & Registries Subcommittee, ESC Committee for Practice Guidelines (CPG), Document Reviewers, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Task Force for the Universal Definition of Myocardial Infarction, Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012; 33(20): 2551–2567, doi: 10.1093/eurheartj/ehs184, indexed in Pubmed: 22922414.
251. Ibanez B, James S, Agewall S, et al. Widimsky P; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119–177, doi: doi: 10.1093/eurheartj/ehx393.
252. Shade G, Ross G, Bever F, et al. Troponin I in the diagnosis of acute myocardial infarction in pregnancy, labor, and post partum. American Journal of Obstetrics and Gynecology. 2002; 187(6): 1719–1720, doi: 10.1067/mob.2002.126648.
253. Joyal D, Leya F, Koh M, et al. Troponin I levels in patients with preeclampsia. Am J Med. 2007; 120(9): 819.e13–819.e14, doi: 10.1016/j.amjmed.2006.05.068, indexed in Pubmed: 17765054.
254. Lancellotti P, Price S, Edvardsen T, et al. The use of echocardiography in acute cardiovascular care: Recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care. 2015; 4: 3–5, doi: 10.1177/2048872614568073.
255. Mahmoud AN, Taduru SS, Mentias A, et al. Trends of Incidence, Clinical Presentation, and In-Hospital Mortality Among Women With Acute Myocardial Infarction With or Without Spontaneous Coronary Artery Dissection: A Population-Based Analysis. JACC Cardiovasc Interv. 2018; 11(1): 80–90, doi: 10.1016/j.jcin.2017.08.016, indexed in Pubmed: 29248409.
256. Jeejeebhoy FM, Zelop CM, Lipman S, et al. American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015; 132(18): 1747–1773, doi: 10.1161/CIR.0000000000000300, indexed in Pubmed: 26443610.
257. Frishman W, Elkayam U, Aronow W. Cardiovascular Drugs in Pregnancy. Cardiology Clinics. 2012; 30(3): 463–491, doi: 10.1016/j.ccl.2012.04.007.
258. Tweet MS, Hayes SN, Gulati R, et al. Pregnancy after spontaneous coronary artery dissection: a case series. Ann Intern Med. 2015; 162(8): 598–600, doi: 10.7326/L14-0446, indexed in Pubmed: 25894037.
259. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant patient. AJR Am J Roentgenol. 2013; 200(3): 515–521, doi: 10.2214/AJR.12.9864, indexed in Pubmed: 23436839.
260. Burchill LJ, Lameijer H, Roos-Hesselink JW, et al. Pregnancy risks in women with pre-existing coronary artery disease, or following acute coronary syndrome. Heart. 2015; 101(7): 525–529, doi: 10.1136/heartjnl-2014-306676, indexed in Pubmed: 25564557.
261. Dufour PH, Occelli B, Puech F. Pregnancy after myocardial infarction. Int J Gynaecol Obstet. 1997; 59(3): 251–253, indexed in Pubmed: 9486516.
262. Bagg W, Henley PG, Macpherson P, et al. Pregnancy in women with diabetes and ischaemic heart disease. Aust N Z J Obstet Gynaecol. 1999; 39(1): 99–102, indexed in Pubmed: 10099760.
263. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12: 767–778, doi: doi: 10.1093/eurjhf/hfq120, indexed in Pubmed: 20675664.
264. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015; 36(18): 1090–1097, doi: 10.1093/eurheartj/ehv009, indexed in Pubmed: 25636745.
265. Sliwa K, Hilfiker-Kleiner D, Mebazaa A, et al. EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail. 2014; 16(5): 583–591, doi: 10.1002/ejhf.68, indexed in Pubmed: 24591060.
266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017; 19: 1131–1141, doi: doi: 10.1002/ejhf.780, indexed in Pubmed: 28271625.
267. Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006; 27(4): 441–446, doi: 10.1093/eurheartj/ehi481, indexed in Pubmed: 16143707.
268. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123(5): 2143–2154, doi: 10.1172/JCI64365, indexed in Pubmed: 23619365.
269. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012; 485(7398): 333–338, doi: 10.1038/nature11040, indexed in Pubmed: 22596155.
270. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol. 2015; 110(6): 60, doi: 10.1007/s00395-015-0517-2, indexed in Pubmed: 26519371.
271. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128(3): 589–600, doi: 10.1016/j.cell.2006.12.036, indexed in Pubmed: 17289576.
272. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012; 33(12): 1469–1479, doi: 10.1093/eurheartj/ehr485, indexed in Pubmed: 22307461.
273. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010; 121(20): 2176–2182, doi: 10.1161/CIRCULATIONAHA.109.931220, indexed in Pubmed: 20458009.
274. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010; 121(20): 2169–2175, doi: 10.1161/CIRCULATIONAHA.109.929646, indexed in Pubmed: 20458010.
275. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014; 35(32): 2165–2173, doi: 10.1093/eurheartj/ehu050, indexed in Pubmed: 24558114.
276. Ware JS, Li J, Mazaika E, et al. IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomy-

opathies. N Engl J Med. 2016; 374(3): 233–241, doi: 10.1056/NEJMoa1505517, indexed in Pubmed: 26735901.
277. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013; 108(4): 366, doi: 10.1007/s00395-013-0366-9, indexed in Pubmed: 23812247.
278. McNamara DM, Elkayam U, Alharethi R, et al. IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66(8): 905–914, doi: 10.1016/j.jacc.2015.06.1309, indexed in Pubmed: 26293760.
279. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016; 18(9): 1096–1105, doi: 10.1002/ejhf.586, indexed in Pubmed: 27338866.
280. Honigberg MC, Givertz MM. Arrhythmias in peripartum cardiomyopathy. Card Electrophysiol Clin. 2015; 7(2): 309–317, doi: 10.1016/j.ccep.2015.03.010, indexed in Pubmed: 26002395.
281. Haghikia A, Röntgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Fail. 2015; 2(4): 139–149, doi: 10.1002/ehf2.12059, indexed in Pubmed: 27774259.
282. Blauwet LA, Delgado-Montero A, Ryo K, et al. IPAC Investigators*. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes. Circ Heart Fail. 2016; 9(5), doi: 10.1161/CIRCHEARTFAILURE.115.002756, indexed in Pubmed: 27166247.
283. Libhaber E, Sliwa K, Bachelier K, et al. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol. 2015; 190: 376–382, doi: 10.1016/j.ijcard.2015.04.081, indexed in Pubmed: 25966297.
284. Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012; 14(8): 895–901, doi: 10.1093/eurjhf/hfs070, indexed in Pubmed: 22588321.
285. Hilfiker-Kleiner D, Haghikia A, Masuko D, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure. 2017; 19(12): 1723–1728, doi: 10.1002/ejhf.808.
286. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200, doi: 10.1093/eurheartj/ehw128, indexed in Pubmed: 27206819.
287. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10(9): 531–547, doi: 10.1038/nrcardio.2013.105, indexed in Pubmed: 23900355.
288. Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol. 2009; 55(1): 45–52, doi: 10.1016/j.jacc.2009.08.036, indexed in Pubmed: 20117363.
289. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015; 17(6): 544–558, doi: 10.1002/ejhf.289, indexed in Pubmed: 25999021.
290. Hilfiker-Kleiner D, Westhoff-Bleck M, Gunter HH, et al. A management algorithm for acute heart failure in pregnancy. The Hannover experience. Eur Heart J. 2015; 36(13): 769–770, indexed in Pubmed: 26000354.
291. Stapel B, Kohlhaas M, Ricke-Hoch M, et al. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J. 2017; 38(5): 349–361, doi: 10.1093/eurheartj/ehw086, indexed in Pubmed: 28201733.
292. Labbene I, Arrigo M, Tavares M, et al. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2017; 36(1): 39–42, doi: 10.1016/j.accpm.2016.02.009, indexed in Pubmed: 27436451.
293. Haghikia A, Tongers J, Berliner D, et al. Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. Int J Cardiol. 2016; 216: 165–167, doi: 10.1016/j.ijcard.2016.04.143, indexed in Pubmed: 27156059.
294. Haghikia A, Podewski E, Berliner D, et al. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol. 2015; 104(11): 911–917, doi: 10.1007/s00392-015-0869-5, indexed in Pubmed: 26026286.
295. Desplantie O, Tremblay-Gravel M, Avram R, et al. BRO-HF Initiative Investigators. The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies. Can J Cardiol. 2015; 31(12): 1421–1426, doi: 10.1016/j.cjca.2015.04.029, indexed in Pubmed: 26160409.
296. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J. 2017; 38(35): 2680–2682, doi: 10.1093/eurheartj/ehx428, indexed in Pubmed: 28934838.
297. Duncker D, Haghikia A, König T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014; 16(12): 1331–1336, doi: 10.1002/ejhf.188, indexed in Pubmed: 25371320.
298. Duncker D, König T, Hohmann S, et al. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. J Am Heart Assoc. 2017; 6(1), doi: 10.1161/JAHA.116.004512, indexed in Pubmed: 28096098.
299. Køber L, Thune J, Nielsen J, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine. 2016; 375(13): 1221–1230, doi: 10.1056/nejmoa1608029.
300. Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012; 31(2): 180–186, doi: 10.1016/j.healun.2011.11.018, indexed in Pubmed: 22305380.
301. Abdalla M, Mancini DM. Management of pregnancy in the post-cardiac transplant patient. Semin Perinatol. 2014; 38(5): 318–325, doi: 10.1053/j.semperi.2014.04.022, indexed in Pubmed: 25037523.
302. O'Boyle PJ, Smith JD, Danskine AJ, et al. De novo HLA sensitization and antibody mediated rejection following pregnancy in a heart transplant recipient. Am J Transplant. 2010; 10(1): 180–183, doi: 10.1111/j.1600-6143.2009.02875.x, indexed in Pubmed: 19951281.
303. Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29(8): 914–956, doi: 10.1016/j.healun.2010.05.034, indexed in Pubmed: 20643330.
304. McKay DB, Josephson MA, Armenti VT, et al. Women's Health Committee of the American Society of Transplantation. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005; 5(7): 1592–1599, doi: 10.1111/j.1600-6143.2005.00969.x, indexed in Pubmed: 15943616.
305. Bhagra CJ, Bhagra SK, Donado A, et al. Pregnancy in cardiac transplant recipients. Clin Transplant. 2016; 30(9): 1059–1065, doi: 10.1111/ctr.12788, indexed in Pubmed: 27313061.
306. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962, doi: 10.1093/eurheartj/ehw210, indexed in Pubmed: 27567408.
307. Metra M. September 2016 at a glance: pregnancy, hypertrophic cardiomyopathy, epidemiology, medical treatment. Eur J Heart Fail. 2016; 18(9): 1091–1092, doi: 10.1002/ejhf.627, indexed in Pubmed: 27594173.

308. Schinkel AFL. Pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev. 2014; 22(5): 217–222, doi: 10.1097/CRD.0000000000000010, indexed in Pubmed: 25093741.
309. Van Tintelen JP, Pieper PG, Van Spaendonck-Zwarts KY, et al. Pregnancy, cardiomyopathies, and genetics. Cardiovasc Res. 2014; 101(4): 571–578, doi: 10.1093/cvr/cvu014, indexed in Pubmed: 24451172.
310. Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ. 2006; 332(7552): 1251–1255, doi: 10.1136/bmj.332.7552.1251, indexed in Pubmed: 16735335.
311. Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40(10): 1864–1869, indexed in Pubmed: 12446072.
312. Tanaka H, Kamiya C, Katsuragi S, et al. Cardiovascular events in pregnancy with hypertrophic cardiomyopathy. Circ J. 2014; 78(10): 2501–2506, indexed in Pubmed: 25099604.
313. Pieper PG, Walker F. Pregnancy in women with hypertrophic cardiomyopathy. Neth Heart J. 2013; 21(1): 14–18, doi: 10.1007/s12471-012-0358-7, indexed in Pubmed: 23212678.
314. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962, doi: 10.1093/eurheartj/ehw210, indexed in Pubmed: 27567408.
315. Sideris S, Kasiakogias A, Aggeli C, et al. Implantation of a defibrillator in a pregnant woman with hypertrophic cardiomyopathy under echocardiographic guidance: a case report. Int J Cardiol. 2015; 179: 323–324, doi: 10.1016/j.ijcard.2014.11.091, indexed in Pubmed: 25464476.
316. Lüscher TF. Device therapy in cardiac disease: a success story. Eur Heart J. 2015; 36(37): 2473–2475, doi: 10.1093/eurheartj/ehv411, indexed in Pubmed: 26429906.
317. Ashikhmina E, Farber MK, Mizuguchi KA. Parturients with hypertrophic cardiomyopathy: case series and review of pregnancy outcomes and anesthetic management of labor and delivery. Int J Obstet Anesth. 2015; 24(4): 344–355, doi: 10.1016/j.ijoa.2015.07.002, indexed in Pubmed: 26350523.
318. Vaidya VR, Arora S, Patel N, et al. Burden of Arrhythmia in Pregnancy. Circulation. 2017; 135(6): 619–621, doi: 10.1161/CIRCULATIONAHA.116.026681, indexed in Pubmed: 28154000.
319. Li JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol. 2008; 31(11): 538–541, doi: 10.1002/clc.20326, indexed in Pubmed: 19006111.
320. Lee MS, Chen W, Zhang Z, et al. Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study. J Am Heart Assoc. 2016; 5(4): e003182, doi: 10.1161/JAHA.115.003182, indexed in Pubmed: 27076563.
321. Opotowsky AR, Siddiqi OK, D'Souza B, et al. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart. 2012; 98(2): 145–151, doi: 10.1136/heartjnl-2011-300828, indexed in Pubmed: 21990383.
322. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006; 97(8): 1206–1212, doi: 10.1016/j.amjcard.2005.11.041, indexed in Pubmed: 16616027.
323. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998; 97(5): 451–456, indexed in Pubmed: 9490239.
324. Hodes AR, Tichnell C, Te Riele AS, et al. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart. 2016; 102(4): 303–312, doi: 10.1136/heartjnl-2015-308624, indexed in Pubmed: 26719359.
325. Chang SH, Kuo CF, Chou IJ, et al. Outcomes Associated With Paroxysmal Supraventricular Tachycardia During Pregnancy. Circulation. 2017; 135(6): 616–618, doi: 10.1161/CIRCULATIONAHA.116.025064, indexed in Pubmed: 28153999.
326. Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol. 1995; 75(7): 521–523, indexed in Pubmed: 7864004.
327. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003; 42(8): 1493–1531, indexed in Pubmed: 14563598.
328. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67: 1575–1623, doi: 10.1016/j.jacc.2015.09.019., indexed in Pubmed: 26409258.
329. Kockova R, Kocka V, Kiernan T, et al. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol. 2007; 18(5): 545–547, doi: 10.1111/j.1540-8167.2006.00752.x, indexed in Pubmed: 17286570.
330. Miyoshi T, Kamiya CA, Katsuragi S, et al. Safety and efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. Circ J. 2013; 77(5): 1166–1170, indexed in Pubmed: 23291990.
331. Nakagawa M, Katou S, Ichinose M, et al. Characteristics of new--onset ventricular arrhythmias in pregnancy. J Electrocardiol. 2004; 37(1): 47–53, indexed in Pubmed: 15132369.
332. Ishibashi K, Aiba T, Kamiya C, et al. Arrhythmia risk and -blocker therapy in pregnant women with long QT syndrome. Heart. 2017; 103(17): 1374–1379, doi: 10.1136/heartjnl-2016-310617, indexed in Pubmed: 28292826.
333. Friday KP, Moak JP, Fries MH, et al. Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible? Pediatr Cardiol. 2015; 36(7): 1542–1547, doi: 10.1007/s00246-015-1232-3, indexed in Pubmed: 26278400.
334. Hidaka N, Chiba Y, Fukushima K, et al. Pregnant women with complete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol. 2011; 34(9): 1161–1176, doi: 10.1111/j.1540-8159.2011.03177.x, indexed in Pubmed: 21797903.
335. Suri V, Keepanasseril A, Aggarwal N, et al. Maternal complete heart block in pregnancy: analysis of four cases and review of management. J Obstet Gynaecol Res. 2009; 35(3): 434–437, doi: 10.1111/j.1447-0756.2008.00961.x, indexed in Pubmed: 19527379.
336. Wang YC, Chen CH, Su HY, et al. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol. 2006; 126(2): 268–269, doi: 10.1016/j.ejogrb.2005.11.021, indexed in Pubmed: 16377063.
337. Page R. Treatment of arrhythmias during pregnancy. American Heart Journal. 1995; 130(4): 871–876, doi: 10.1016/0002-8703(95)90090-x.
338. Moore JS, Teefey P, Rao K, et al. Maternal arrhythmia: a case report and review of the literature. Obstet Gynecol Surv. 2012; 67(5): 298–312, doi: 10.1097/OGX.0b013e318253a76e, indexed in Pubmed: 22624778.
339. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002; 109(12): 1406–1407, indexed in Pubmed: 12504980.
340. Natale A, Davidson T, Geiger MJ, et al. Implantable cardioverter--defibrillators and pregnancy: a safe combination? Circulation. 1997; 96(9): 2808–2812, indexed in Pubmed: 9386142.
341. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015; 65(16): 1605–1615, doi: 10.1016/j.jacc.2015.02.047, indexed in Pubmed: 25908064.
342. Strewe C, Fichtner S. [Completely subcutaneous implantable cardioverter defibrillator: Care of S-ICD wearers during childbirth]. Anaesthesist. 2015; 64(11): 843–845, doi: 10.1007/s00101-015-0082-y, indexed in Pubmed: 26341078.
343. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012; 18(1): 21–27, doi: 10.1016/j.cardfail.2011.09.004, indexed in Pubmed: 22196837.

344. Hartz J, Clark BC, Ito S, et al. Transvenous nonfluoroscopic pacemaker implantation during pregnancy guided by 3-dimensional electroanatomic mapping. HeartRhythm Case Rep. 2017; 3(10): 490–492, doi: 10.1016/j.hrcr.2017.07.020, indexed in Pubmed: 29062705.
345. Villar J, Carroli G, Wojdyla D, et al. World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006; 194(4): 921–931, doi: 10.1016/j.ajog.2005.10.813, indexed in Pubmed: 16580277.
346. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 1990; 163(5 Pt 1): 1691–1712, indexed in Pubmed: 2104525.
347. Levine RJ, Ewell MG, Hauth JC, et al. Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥15 mm Hg to a level <90 mm Hg in association with proteinuria? American Journal of Obstetrics and Gynecology. 2000; 183(4): 787–792, doi: 10.1067/mob.2000.108865.
348. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357, doi: 10.1097/01.hjh.0000431740.32696.cc, indexed in Pubmed: 23817082.
349. dablVR Educational Trust. www.dableducation.org.
350. Blood Pressure UK. http://www.bloodpressureuk.org.
351. Waugh J, Perry IJ, Halligan AW, et al. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am J Obstet Gynecol. 1998; 178(3): 521–526, indexed in Pubmed: 9539520.
352. Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of--office BP measurement in hypertensive pregnancy? Hypertens Pregnancy. 2008; 27(2): 95–101, doi: 10.1080/10641950801950197, indexed in Pubmed: 18484418.
353. Schmella MJ, Clifton RG, Althouse AD, et al. Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women? Reprod Sci. 2015; 22(10): 1212–1219, doi: 10.1177/1933719115572477, indexed in Pubmed: 25717062.
354. Cade TJ, de Crespigny PC, Nguyen T, et al. Should the spot albumin--to-creatinine ratio replace the spot protein-to-creatinine ratio as the primary screening tool for proteinuria in pregnancy? Pregnancy Hypertens. 2015; 5(4): 298–302, doi: 10.1016/j.preghy.2015.07.001, indexed in Pubmed: 26597744.
355. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ. 2008; 336(7651): 968–969, doi: 10.1136/bmj.39540.657928.BE, indexed in Pubmed: 18403497.
356. Côté AM, Firoz T, Mattman A, et al. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol. 2008; 199(6): 625.e1–625.e6, doi: 10.1016/j.ajog.2008.06.009, indexed in Pubmed: 18718568.
357. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008; 178(6): 701–711, doi: 10.1503/cmaj.070430, indexed in Pubmed: 18332385.
358. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1): 13–22, doi: 10.1056/NEJMoa1414838, indexed in Pubmed: 26735990.
359. Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, et al. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens. 2012; 30(11): 2173–2181, doi: 10.1097/HJH.0b013e328357c0c9, indexed in Pubmed: 22902831.
360. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122(5): 1122–1131, doi: 10.1097/01.AOG.0000437382.03963.88, indexed in Pubmed: 24150027.
361. Magee LA, Pels A, Helewa M, et al. SOGC Hypertension Guideline Committee, Canadian Hypertensive Disorders of Pregnancy Working Group, Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4(2): 105–145, doi: 10.1016/j.preghy.2014.01.003, indexed in Pubmed: 26104418.
362. Lowe SA, Bowyer L, Lust K, et al. Society of Obstetric Medicine of Australia and New Zealand. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015; 55(1): 11–16, doi: 10.1111/ajo.12253, indexed in Pubmed: 25308532.
363. Bartsch E, Medcalf KE, Park AL, et al. High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016; 353: i1753, doi: 10.1136/bmj.i1753, indexed in Pubmed: 27094586.
364. National Collaborating Centre for Women's and Children's Health (UK). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press; 2010.
365. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377(7): 613–622, doi: 10.1056/NEJMoa1704559, indexed in Pubmed: 28657417.
366. Hofmeyr GJ, Lawrie TA, Atallah AN, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014; 6: CD001059.
367. Xu H, Perez-Cuevas R, Xiong Xu, et al. INTAPP study group. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol. 2010; 202(3): 239.e1–239.e10, doi: 10.1016/j.ajog.2010.01.050, indexed in Pubmed: 20207239.
368. Villar J, Purwar M, Merialdi M, et al. WHO Vitamin C and Vitamin E trial group. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG. 2009; 116(6): 780–788, doi: 10.1111/j.1471-0528.2009.02158.x, indexed in Pubmed: 19432566.
369. Spinnato JA, Freire S, Pinto E Silva JL, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol. 2007; 110(6): 1311–1318, doi: 10.1097/01.AOG.0000289576.43441.1f, indexed in Pubmed: 18055726.
370. Poston L, Briley AL, Seed PT, et al. Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006; 367(9517): 1145–1154, doi: 10.1016/S0140--6736(06)68433-X, indexed in Pubmed: 16616557.
371. Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976; 2(7989): 753–756, indexed in Pubmed: 61439.
372. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982; 1(8273): 647–649, indexed in Pubmed: 6121965.
373. Magee L, Dadelszen Pv, Rey E, et al. Less-Tight versus Tight Control of Hypertension in Pregnancy. New England Journal of Medicine. 2015; 372(5): 407–417, doi: 10.1056/nejmoa1404595.
374. Magee LA, von Dadelszen P, Singer J, et al. CHIPS Study Group*. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure? Hypertension. 2016; 68(5): 1153–1159, doi: 10.1161/HYPERTENSIONAHA.116.07862, indexed in Pubmed: 27620393.
375. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014; 2: CD002252.
376. Dodd JM, Turnbull D, McPhee AJ, et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ. 2014; 348(feb10 3): g1285–g1285, doi: 10.1136/bmj.g1285.
377. Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev Obstet Gynecol. 2008; 1(4): 170–178, indexed in Pubmed: 19173021.
378. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003; 327(7421): 955–960, doi: 10.1136/bmj.327.7421.955, indexed in Pubmed: 14576246.
379. Vigil-De Gracia P, Lasso M, Ruiz E, et al. or the HYLA treatment study. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;

128(1-2): 157–162, doi: 10.1016/j.ejogrb.2006.02.015, indexed in Pubmed: 16621226.
380. Shekhar S, Gupta N, Kirubakaran R, et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016; 123(1): 40–47, doi: 10.1111/1471-0528.13463, indexed in Pubmed: 26113232.
381. Clark SM, Dunn HE, Hankins GDV. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015; 39(7): 548–555, doi: 10.1053/j.semperi.2015.08.011, indexed in Pubmed: 26344738.
382. Altman D, Carroli G, Duley L, et al. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002; 359(9321): 1877–1890, indexed in Pubmed: 12057549.
383. Koopmans CM, Bijlenga D, Groen H, et al. HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374(9694): 979–988, doi: 10.1016/S0140-6736(09)60736-4, indexed in Pubmed: 19656558.
384. Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy. 2010; 29(3): 294–300, doi: 10.3109/10641950902777747, indexed in Pubmed: 20670153.
385. Beardmore KS, Morris JM, Gallery EDM. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002; 21(1): 85–95, doi: 10.1081/PRG-120002912, indexed in Pubmed: 12044345.
386. Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005; 366(9499): 1797–1803, doi: 10.1016/S0140-6736(05)67726-4, indexed in Pubmed: 16298217.
387. Black MH, Zhou H, Sacks DA, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. J Hypertens. 2016; 34(4): 728–735, doi: 10.1097/HJH.0000000000000855, indexed in Pubmed: 26809018.
388. Wang YA, Chughtai AA, Farquhar CM, et al. Increased incidence of gestational hypertension and preeclampsia after assisted reproductive technology treatment. Fertil Steril. 2016; 105(4): 920–926.e2, doi: 10.1016/j.fertnstert.2015.12.024, indexed in Pubmed: 26780118.
389. Hoeltzenbein M, Beck E, Fietz AK, et al. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017; 70(1): 201–208, doi: 10.1161/HYPERTENSIONAHA.117.09110, indexed in Pubmed: 28533329.
390. Liu S, Rouleau J, Joseph KS, et al. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can. 2009; 31(7): 611–620, doi: 10.1016/S1701-2163(16)34240-2, indexed in Pubmed: 19761634.
391. O'Connor DJ, Scher LA, Gargiulo NJ, et al. Incidence and characteristics of venous thromboembolic disease during pregnancy and the postnatal period: a contemporary series. Ann Vasc Surg. 2011; 25(1): 9–14, doi: 10.1016/j.avsg.2010.04.003, indexed in Pubmed: 20800436.
392. Rutherford SE, Phelan JP. Deep venous thrombosis and pulmonary embolism in pregnancy. Obstet Gynecol Clin North Am. 1991; 18(2): 345–370, indexed in Pubmed: 1945260.
393. Sullivan EA, Ford JB, Chambers G, et al. Maternal mortality in Australia, 1973-1996. Aust N Z J Obstet Gynaecol. 2004; 44(5): 452–7; discussion 377, doi: 10.1111/j.1479-828X.2004.00313.x, indexed in Pubmed: 15387869.
394. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10): 697–706, indexed in Pubmed: 16287790.
395. Meng K, Hu X, Peng X, et al. Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2015; 28(3): 245–253, doi: 10.3109/14767058.2014.913130, indexed in Pubmed: 24716782.
396. Knight M. UKOSS. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG. 2008; 115(4): 453–461, doi: 10.1111/j.1471-0528.2007.01622.x, indexed in Pubmed: 18201281.
397. Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol. 2012; 156(3): 366–373, doi: 10.1111/j.1365-2141.2011.08956.x, indexed in Pubmed: 22145820.
398. Galambosi PJ, Ulander VM, Kaaja RJ. The incidence and risk factors of recurrent venous thromboembolism during pregnancy. Thromb Res. 2014; 134(2): 240–245, doi: 10.1016/j.thromres.2014.04.026, indexed in Pubmed: 24835671.
399. Roeters van Lennep JE, Meijer E, Klumper FJ, et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost. 2011; 9(3): 473–480, doi: 10.1111/j.1538-7836.2011.04186.x, indexed in Pubmed: 21232006.
400. Sultan AA, Tata LJ, West J, et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood. 2013; 121(19): 3953–3961, doi: 10.1182/blood-2012-11-469551, indexed in Pubmed: 23550034.
401. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Royal College of Obstetricians and Gynaecologists Green-Top Guideline No. 37a. London: Royal College of Obstetricians and Gynaecologists. ; 2009.
402. Bauersachs RM, Dudenhausen J, Faridi A, et al. EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost. 2007; 98(6): 1237–1245, indexed in Pubmed: 18064320.
403. Stephenson ML, Serra AE, Neeper JM, et al. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. J Perinatol. 2016; 36(2): 95–99, doi: 10.1038/jp.2015.130, indexed in Pubmed: 26658126.
404. Overcash RT, Somers AT, LaCoursiere DY. Enoxaparin dosing after cesarean delivery in morbidly obese women. Obstet Gynecol. 2015; 125(6): 1371–1376, doi: 10.1097/AOG.0000000000000873, indexed in Pubmed: 26000508.
405. Konstantinides SV, Torbicki A, Agnelli G, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033–69, 3069a, doi: 10.1093/eurheartj/ehu283, indexed in Pubmed: 25173341.
406. Nijkeuter M, Ginsberg JS, Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost. 2006; 4(3): 496–500, doi: 10.1111/j.1538-7836.2005.01779.x, indexed in Pubmed: 16405518.
407. Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem. 2005; 51(5): 825–829, doi: 10.1373/clinchem.2004.044883, indexed in Pubmed: 15764641.
408. To MS, Hunt BJ, Nelson-Piercy C. A negative D-dimer does not exclude venous thromboembolism (VTE) in pregnancy. J Obstet Gynaecol. 2008; 28(2): 222–223, doi: 10.1080/01443610801915975, indexed in Pubmed: 18393025.
409. Van der Pol LM, Mairuhu ATA, Tromeur C, et al. Use of clinical prediction rules and D-dimer tests in the diagnostic management of pregnant patients with suspected acute pulmonary embolism. Blood Rev. 2017; 31(2): 31–36, doi: 10.1016/j.blre.2016.09.003, indexed in Pubmed: 27720446.
410. Konstantinides SV, Barco S, Lankeit M, et al. Management of Pulmonary Embolism: An Update. J Am Coll Cardiol. 2016; 67(8): 976–990, doi: 10.1016/j.jacc.2015.11.061, indexed in Pubmed: 26916489.
411. O'Connor C, Moriarty J, Walsh J, et al. The application of a clinical risk stratification score may reduce unnecessary investigations for pulmonary embolism in pregnancy. J Matern Fetal Neonatal Med. 2011; 24(12): 1461–1464, doi: 10.3109/14767058.2011.614652, indexed in Pubmed: 21854126.
412. Parilla BV, Fournogerakis R, Archer A, et al. Diagnosing Pulmonary Embolism in Pregnancy: Are Biomarkers and Clinical Predictive Models Useful? AJP Rep. 2016; 6(2): e160–e164, doi: 10.1055/s-0036-1582136, indexed in Pubmed: 27119048.
413. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 844S–886S, doi: 10.1378/chest.08-0761, indexed in Pubmed: 18574280.
414. Ahearn GS, Hadjiliadis D, Govert JA, et al. Massive pulmonary embolism during pregnancy successfully treated with recombinant

tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med. 2002; 162(11): 1221–1227, indexed in Pubmed: 12038939.
415. Chan WS, Lee A, Spencer FA, et al. Predicting deep venous thrombosis in pregnancy: out in. Ann Intern Med. 2009; 151(2): 85–92, indexed in Pubmed: 19620161.
416. Le Gal G, Kercret G, Ben Yahmed K, et al. EDVIGE Study Group. Diagnostic value of single complete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: prospective study. BMJ. 2012; 344: e2635, doi: 10.1136/bmj.e2635, indexed in Pubmed: 22531869.
417. Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol. 2009; 145(6): 825–835, doi: 10.1111/j.1365-2141.2009.07698.x, indexed in Pubmed: 19388925.
418. Sennström M, Rova K, Hellgren M, et al. Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand. 2017; 96(9): 1045–1052, doi: 10.1111/aogs.13147, indexed in Pubmed: 28382684.
419. McLintock C, Brighton T, Chunilal S, et al. Councils of the Society of Obstetric Medicine of Australia and New Zealand, Australasian Society of Thrombosis and Haemostasis. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol. 2012; 52(1): 14–22, doi: 10.1111/j.1479-828X.2011.01361.x, indexed in Pubmed: 21972999.
420. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016; 41(1): 206–232, doi: 10.1007/s11239-015-1310-7, indexed in Pubmed: 26780747.
421. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol. 2010; 30(4): 253–257, doi: 10.1038/jp.2009.164, indexed in Pubmed: 19829297.
422. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv. 1995; 50(7): 534–541, indexed in Pubmed: 7566831.
423. De Carolis S, di Pasquo E, Rossi E, et al. Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. Thromb Res. 2015; 135(6): 1049–1051, doi: 10.1016/j.thromres.2015.04.001, indexed in Pubmed: 25912931.
424. Dempfle CEH. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004; 350(18): 1914–1915, doi: 10.1056/NEJM200404293501825, indexed in Pubmed: 15115845.
425. Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost. 2016; 116(4): 651–658, doi: 10.1160/TH16-04-0305, indexed in Pubmed: 27384740.
426. Garg J, Palaniswamy C, Lanier GM. Peripartum cardiomyopathy: definition, incidence, etiopathogenesis, diagnosis, and management. Cardiol Rev. 2015; 23(2): 69–78, doi: 10.1097/CRD.0000000000000038, indexed in Pubmed: 25111318.
427. Tanaka K, Tanaka H, Maki S, et al. Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease. Circ J. 2016; 80(10): 2221–2226, doi: 10.1253/circj.CJ-15-0617, indexed in Pubmed: 27593227.
428. Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol. 1997; 79(10): 1436–1438, indexed in Pubmed: 9165181.
429. Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011; 20(2): 138–145, doi: 10.1002/pds.2068, indexed in Pubmed: 21254284.
430. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother. 2012; 46(10): 1419–1424, doi: 10.1345/aph.1R202, indexed in Pubmed: 23032657.
431. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013; 120(4): 463–471, doi: 10.1111/1471-0528.12066, indexed in Pubmed: 23194157.
432. U.S. Food & Drug Administration. Pregnancy and lactation labeling (drugs) final rule. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Development Resources/Labeling/ucm093307.htm.
433. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996; 174(3): 823–828, indexed in Pubmed: 8633650.
434. Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol. 2008; 26(1): 24–30, doi: 10.1016/j.reprotox.2008.05.065, indexed in Pubmed: 18585452.
435. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol. 2003; 67(8): 591–594, doi: 10.1002/bdra.10081, indexed in Pubmed: 14632309.
436. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354(23): 2443–2451, doi: 10.1056/NEJMoa055202, indexed in Pubmed: 16760444.
437. American Academy of Committee on Drugs. American Academy of Committee on Drugs: The transfer of drugs and other chemicals into human milk. Pediatrics. 1994; 93: 137–150.
438. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004; 10(7 Pt 2): 481–486, indexed in Pubmed: 15298234.
439. Podymow T, August P. Antihypertensive Drugs in Pregnancy. Seminars in Nephrology. 2011; 31(1): 70–85, doi: 10.1016/j.semnephrol.2010.10.007.